

Acknowledgements

The study was supported by a research grant from the Asociación para la Investigación en Reumatología de la Marina Baixa (AIRE-MB).

References

1. Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. *Rheumatology*. 2019;58:1755–66.
2. Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, et al. Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate. *Arthritis Care Res (Hoboken)*. 2019;71:1249–54.
3. O'shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. *N Engl J Med*. 2013;368:161–70.
4. Kubo S, Nakayama S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis. *Expert Rev Clin Immunol*. 2016;12:911–9.
5. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. *Ann Rheum Dis*. 2015;74:333–40.
6. Genovese MC, Kremer J, Zamani O, Ludvico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. *N Engl J Med*. 2016;374:1243–52.
7. Taylor PC, Keystone EC, Van Der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*. 2017;376:652–62.
8. van Vollenhoven R, Helt C, Arora V, Zhong J, Correia AP, de la Torre I, et al. Safety and efficacy of baricitinib in patients receiving conventional synthetic

- disease-modifying antirheumatic drugs or corticosteroids. *Rheumatol Ther*. 2018;5:525–36.
9. Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. *J Rheumatol*. 2019;46:7–18.
 10. Tan J, Davies S, Linton S. E061. Retrospective cohort study of early real-life experience with baricitinib in rheumatoid arthritis. *Rheumatology*. 2019;58 Suppl 3, <http://dx.doi.org/10.1093/rheumatology/kez110.059>.
 11. Fitton J, Dass S, Emery P, Nam J, Maya HB. 087. Janus kinase inhibitors demonstrate effectiveness in a real-world multi-biologic DMARD refractory rheumatoid arthritis population. *Rheumatology*. 2019;58 Suppl 3, <http://dx.doi.org/10.1093/rheumatology/kez106.086>.

José Rosas,^{a,*} José Miguel Senabre-Gallego,^{a,b,c}
Gregorio Santos-Soler,^{a,b,c} José Antonio Bernal,^{a,b,c}
Ana Pons Bas^{a,b,c}, Grupo Aire-Mb

^a Sección de Reumatología, Hospital Marina Baixa, Villajoyosa, Alicante, Spain

^b Sección de Enfermedades Infecciosas, Hospital General Universitario de Elche, Alicante, Spain

^c CIO-Universidad Miguel Hernández, Elche, Alicante, Spain

* Corresponding author.

E-mail address: j.rosas.gs@gmail.com (J. Rosas).

<https://doi.org/10.1016/j.reumae.2020.04.008>

2173-5743/ © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Increasing trend in mortality from systemic lupus erythematosus in Latin America as an expression of social disparities in health[☆]



Tendencia creciente en la mortalidad por lupus eritematoso sistémico en América Latina como expresión de las desigualdades sociales en salud

Dear Editor,

Despite the fact that in the last two decades diagnostic, therapeutic and preventative strategies regarding systemic lupus erythematosus (SLE) have improved, their impact on specific mortality from this disease is as yet unknown.^{1,2} This has led to the use of data from mortality records to undertake cost-effective research studies with a standardised method on the epidemiological behaviour of mortality by SLE at a population level and over long periods of time.^{1,3–5} The resulting evidence of these studies has helped to enhance the understanding of this disease and its recognition as a major health problem for healthcare authorities of several governments.^{2,5,6} However, Latin America is experiencing a very different reality in political material and health reports regarding SLE.

Recently, Scherlinger M et al. published the worldwide trends on mortality from systemic autoimmune diseases during the period from 2001 to 2014 in the journal “Autoimmunity Reviews”. For this they used the mortality database from the World Health Organisation.³ Their main conclusion was the standardised rate of mortality by SLE in Latin America was 5 times greater than that of Europe, a phenomenon which was not observed in the other

systemic autoimmune diseases studied. Furthermore, during the 2003–2014 period, in Latin America and Asia, there was a significantly growing trend in standardised rates of mortality by SLE, whilst in Europe, North America and Oceania they demonstrated there was a decreasing trend and in Africa rates remained stable.³ Posterior analysis by the same authors established an inverse correlation between countries' wealth and the standardized rate of SLE mortality.¹ These research studies confirmed the findings from 3 previous studies on this matter which were based on mortality records, with a similar methodology.^{4,7,8}

Inequality dominates the American continent.⁹ Against this backdrop, much discussion has arisen as to whether the greater severity and mortality observed in Latin American patients with SLE is a consequence of genetic factors or the expression of the influence on health of social determinants in which this patient group lives. The great majority of studies conclude that the main cause of these adverse findings are from the inequalities that affect minority groups where individual factors combine (poverty, malnutrition, lack of treatment compliance, adverse perception and non-adaptive behaviour related to the disease); factors affecting the health system (lack of access to specialised services, geographical isolation) and those caused by society (lack of social support, inadequate public policies and low gross domestic product).^{2,10,11}

It is important to underline that the research studies mentioned share the inherent limitations of the mortality statistics of each country and do not offer information on the causes of death, disease activity or accumulated organ damage. Despite these methodological limitations, their findings are relevant because they identify the tip of the iceberg of this health problem in the region, and urge the Latin American scientific community to recognise and prioritise it.

Low regional evidence on the extension of the problem, its associated factors and the possible effective interventions to address it, are barriers which impede the right decisions being taken and

[☆] Please cite this article as: Hernández-Negrín H, Padilla-Cueto D, Martínez Morales O. Tendencia creciente en la mortalidad por lupus eritematoso sistémico en América Latina como expresión de las desigualdades sociales en salud. *Reumatol Clin*. 2022;18:189–190.

increase the divide between healthcare results for Latin American patients with SLE and the rest of the world.

Over more than a decade has passed since the report by the Commission on Social Determinants of health from the World Health Organisation: *Closing the gap in a generation*. Research and action on individual and contextual determinants which mould health inequalities has been consolidated.^{9,12} This argument increasingly dictates that only an ecological approach from the perspective of social epidemiology will lead to the disentanglement of the causes of the causes of this epidemiological trend in the region and will open the doors to multi-level strategies which lead to its control.

Funding

This research study did not receive any specific grants from public, commercial sector or not-for-profit agencies.

References

- Scherlinger M, Mertz P, Sagez F, Meyer A, Felten A, Chatelus E, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. *Lupus Sci Med*. 2020;7:A1–131, <http://dx.doi.org/10.1136/lupus-2020-eurolupus.19>.
- Drenkard C, Lim SS. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. *Curr Opin Rheumatol*. 2019;31:689–96, <http://dx.doi.org/10.1097/BOR.0000000000000646>.
- Scherlinger M, Mertz P, Sagez F, Meyer A, Felten A, Chatelus E, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. *Autoimmun Rev*. 2020;19:102531, <http://dx.doi.org/10.1016/j.autrev.2020.102531>.
- Rezende R, Vieira C, Gismondi R, Klumb E. Uptrend in mortality from systemic connective tissue diseases: A jointpoint regression analysis among the general population of Brazil, 1996–2016. *Joint Bone Spine*. 2019;86:800–2, <http://dx.doi.org/10.1016/j.jbspin.2019.03.010>.
- Yen EY, Singh RR. Lupus – an unrecognized leading cause of death in young women: population-based study using nationwide death certificates, 2000–2015. *Arthritis Rheumatol*. 2018;70(8):1251–5, <http://dx.doi.org/10.1002/art.40512>.
- Manzi S, Raymond S, Tse K, Peña Y, Anderson A, Arntsen K, et al. Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. *Lupus Sci Med*. 2019;6:e000342, <http://dx.doi.org/10.1136/lupus-2019-000342>.
- Hernández Negrín H. Tendencias en la mortalidad por enfermedades autoinmunes sistémicas en Cuba, 2001–2014. [Tesis]. Villa Clara: Universidad de Ciencias Médicas de Villa Clara; 2020.
- Soares CR, Viana K, Moraes-Santos F, Vieira CL, Lamarão F, Iglesias-Rodríguez M. Mortality rate and premature mortality due to systemic erythematosus lupus in Latin America, US and England and Wales. *Value Health*. 2015;18: A805–81.
- Comisión de la Organización Panamericana de la Salud sobre Equidad y Desigualdades en Salud en las Américas. *Sociedades justas: equidad en la salud y vida digna*. In: Informe de la Comisión de la Organización Panamericana de la Salud sobre Equidad y Desigualdades en Salud en las Américas. Washington, D.C: OPS; 2019.
- Tazi Mezalek Z, Bono W. Challenges for lupus management in emerging countries. *La Presse Med*. 2014;43:e209–20, <http://dx.doi.org/10.1016/j.lpm.2014.04.002>.
- Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. *Nat Rev Rheumatol*. 2016;12:605–20, <http://dx.doi.org/10.1038/nrrheum.2016.137>.
- Organización Mundial de la Salud. *Subsanar las desigualdades en una generación: alcanzar la equidad sanitaria actuando sobre los determinantes sociales de la salud: Informe final de la Comisión de Determinantes Sociales de la Salud*. Washington D.C: OMS; 2009.

Halbert Hernández-Negrín,^{a,*} David Padilla-Cueto,^b
Onan Martínez Morales^c

^a Universidad de Ciencias Médicas de Villa Clara, Santa Clara, Villa Clara, Cuba

^b Hospital Universitario Arnaldo Milián, Santa Clara, Villa Clara, Cuba

^c IPS Asistir Salud, Bogotá, Colombia

* Corresponding author.

E-mail address: halberthn@gmail.com (H. Hernández-Negrín).

<https://doi.org/10.1016/j.reumae.2020.07.005>

2173–5743/ © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.